Defense Industry & Trauma
We are developing trauma specific regenerative transplant constructs for defence & civilian industries
Trauma & Deep Tissue Loss
Traumatic injuries, whether military or civilian, are a leading cause of mortality and morbidity worldwide, accounting for around 10% of the global burden of disease.
Worldwide, 16,000 people succumb to injuries every day, and for every trauma death there are two survivors with serious and debilitating injuries.
Severe trauma has a diverse aetiology. There are, however, certain features common to most cases, including haemorrhage, the presence of hard and soft tissue damage, and pain.
The recent prolonged conflicts in Iraq and Afghanistan saw the advancement of deployed trauma care to a point never before seen in war. The rapid translation of lessons from combat casualty care research, facilitated by an appetite for risk, contributed to year-on-year improvements in care of the injured.
These paradigms, however, can only ever halt the progression of damage.
Regenerative medicine approaches, in contrast, hold a truly disruptive potential to go beyond the cessation of damage from blast or ballistic trauma, to stimulate its reversal, and to do so from a very early point following injury.
The repair and regeneration of severe tissue damage involves a complex set of biological processes involving different structures including vasculature, muscle and neural tissue.
A fine balance of appropriate biological responses must occur for successful functional regeneration and reconstruction.
Impaired wound healing and regeneration are generally associated with the dysregulation of these biological processes.
The mediators involved, including growth factors, cytokines and progenitor cells, have therefore become the focus of wound therapeutics. Biological strategies to aid wound repair and regeneration have largely dominated the wound research area with some successes, including in severe muscle injury.
Combining an understanding of the mechanobiology of relevant wounds with materials science, including nanotechnologies, bio-engineering and biophysics could enable the development of novel, logistically light, early wound management strategies that maintain cellular viability and enhance the regenerative potential of cells within the wound bed during casualty evacuation.
The internationally distributed and, in parts austere environments in which operational medical care is delivered provide an almost unique challenge to the development and translation of regenerative medicine technologies.
In parallel, however, an inherent appetite for risk means that Defence will always be an early adopter.
Source: Regenerative medicine and war: a front-line focus for UK defence
Volumetric Muscle Loss (VML)
Biomaterial-based technologies that enhance host tissue regenerative responses hold significant promise for restoration of functional soft tissue.
Traumatic partial ablation of skeletal muscle, or volumetric muscle loss (VML) injury is particularly in need of an effective regenerative therapy.
VML injury presents a defect region in which all native elements required for canonical skeletal muscle regeneration (e.g., basal lamina and satellite cells) are removed; and, because adult mammalian skeletal muscle is not adept at de novo muscle fiber regeneration or hyperplasia, chronic loss of muscle tissue, persistent strength deficits, and disability manifest.
Encouraging results in animal models, in which implantation of dissociated native muscle elements necessary for canonical muscle fiber regeneration effectively promoted de novo muscle fiber regeneration and neuromuscular functional recovery highlight the potential of regenerative therapeutics.
The challenge now is to delineate which of these native regenerative elements (or their surrogates) must be implanted to instruct and interact with the host in vivo.
Volumetric muscle loss (VML) resulting from extremity trauma presents chronic and persistent functional deficits which ultimately manifest disability.
Unwavering Pathobiology of Volumetric Muscle Loss Injury
BioRegenex is developing Trauma specific regenerative tissue engineering solutions including a 'Trauma Patch' for the traumatic ablation of skeletal muscle & deep tissue loss injuries.